IgG4-related disease (IgG4-RD) is a chronic inflammatory condition. To treat it, doctors often prescribe corticosteroids to reduce inflammation and lower IgG4 levels. But long-term corticosteroid use ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only ...

IgG4-related disease (IgG4-RD) is a chronic autoimmune condition that may affect multiple organs in your body, causing tissue swelling and organ damage. Because no single test can definitively ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis and ...

(MENAFN- GetNews) "IgG4-Related Disease Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Uplizna met all primary and secondary endpoints for ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) with involvement in the pancreas, bile ducts, or liver, according to a post ...

Advances Amgen (AMGN)'s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- ...